Galapagos, Servier Knee Osteoarthritis Trial Fails to Meet Primary, Secondary Endpoints
October 15 2020 - 5:17PM
Dow Jones News
By Kimberly Chin
Galapagos NV and Servier said Thursday that their Phase 2 study
for a treatment for patients with knee osteoarthritis didn't meet
its primary objective.
The double-blind, placebo-controlled study of GLPG1972/S201086
looked at the efficacy of three different once-daily doses on
patients in reducing cartilage loss over a 52-week period. The
cartilage thickness in patients showed no statistically significant
difference between the placebo and any of the treated groups, the
companies said.
The study also failed to meet secondary endpoints, showing no
significant difference in treated patients compared with the
placebo group, the companies said.
Write to Kimberly Chin at kimberly.chin@wsj.com
(END) Dow Jones Newswires
October 15, 2020 17:02 ET (21:02 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Galapagos (EU:GLPG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galapagos (EU:GLPG)
Historical Stock Chart
From Jul 2023 to Jul 2024